



IBA Molecular North America, Inc. acquisition by Illinois Health and Science completes

Louvain-la-Neuve – August 3 2015 - IBA (Ion Beam Applications S.A.), the world's leading provider of proton therapy solutions for the treatment of cancer, announced today the completion of the divestiture of IBA Molecular North America, Inc. (IBAM NA) to Illinois Health and Science (IHS), a non-profit healthcare system.

IBAM NA is the US subsidiary of IBA Molecular (IBAM), a joint-venture owned by IBA S.A. and SK Capital Partners. The acquisition includes all of IBAM NA's cyclotron sites and research and development facilities.

The proceeds will be used to repay outstanding debt at IBAM and to make a distribution to IBAM's shareholders (IBA S.A. owns 40% of IBAM). The transaction is not expected to have a significant impact on IBA's 2015 P&L but will generate cash proceeds of approximately EUR 10 million for IBA during the third quarter of 2015.

*****END*****

About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The Company is the worldwide technology leader in the field of proton therapy, the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full scale proton therapy centers as well as compact, single room systems. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry.

Headquartered in Belgium and employing about 1100 people worldwide, IBA has installed systems across the world, from Europe and the US and to the emerging markets. IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com

About IBA Molecular

IBA Molecular is a leading developer, manufacturer and distributor of radiopharmaceutical products and supporting services used in molecular imaging with operations throughout Europe and Asia. IBA Molecular has a unique product portfolio and pipeline of diagnostic and therapeutic tracers aimed at advancing the development of the global movement towards personalized medicine and making molecular imaging/therapy a major discipline in healthcare. The company also provides educational, technical and marketing support to medical specialists worldwide to help better respond to patient needs. IBA Molecular is jointly owned by SK Capital Partners and IBA (Ion Beam Applications S.A.). For more information, please visit www.ibamolecular.com

Press release |

Regulated information



About Illinois Health and Science

Illinois Health and Science (IHS) is a non-profit healthcare system that specializes in enhancing patient care by making strategic investments in healthcare related opportunities. Focused on enhancing the span, experience, and quality of human life, IHS is a science and technology based firm, with specific focus on creating patient value. Headquartered in Illinois, IHS is led by senior leaders from healthcare and financial services industries. For more information, please visit www.ihsholdings.org

For further information please contact:

IBA

Jean-Marc Bothy

Chief Financial Officer

Tel: +32 10 47 58 90

Thomas Ralet

Vice-President Corporate Communication

+32 10 47 58 90

communication@iba-group.com

For media and investor enquiries:

Consilium Strategic Communications

Amber Fennell, Matthew Neal and Ivar Milligan

+44 (0)20 3709 5700

IBA@consilium-comms.com

Rx Communications Group (US)

Melody Carey

+ 1 917 322 2571

mcarey@RxIR.com